- Home
- SID vs WVE Comparison
SID vs WVE Comparison
Compare SID & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SID
- WVE
- Stock Information
- Founded
- SID 1941
- WVE 2012
- Country
- SID Brazil
- WVE Singapore
- Employees
- SID N/A
- WVE N/A
- Industry
- SID Steel/Iron Ore
- WVE Biotechnology: Pharmaceutical Preparations
- Sector
- SID Industrials
- WVE Health Care
- Exchange
- SID Nasdaq
- WVE Nasdaq
- Market Cap
- SID 2.1B
- WVE 1.7B
- IPO Year
- SID 1997
- WVE 2015
- Fundamental
- Price
- SID $1.54
- WVE $11.13
- Analyst Decision
- SID Sell
- WVE Strong Buy
- Analyst Count
- SID 2
- WVE 10
- Target Price
- SID $2.95
- WVE $21.60
- AVG Volume (30 Days)
- SID 2.0M
- WVE 759.9K
- Earning Date
- SID 03-05-2025
- WVE 03-05-2025
- Dividend Yield
- SID 14.47%
- WVE N/A
- EPS Growth
- SID N/A
- WVE N/A
- EPS
- SID N/A
- WVE N/A
- Revenue
- SID $8,019,254,042.00
- WVE $53,610,000.00
- Revenue This Year
- SID N/A
- WVE N/A
- Revenue Next Year
- SID $6.59
- WVE $48.58
- P/E Ratio
- SID N/A
- WVE N/A
- Revenue Growth
- SID N/A
- WVE N/A
- 52 Week Low
- SID $1.27
- WVE $4.25
- 52 Week High
- SID $3.54
- WVE $16.74
- Technical
- Relative Strength Index (RSI)
- SID 49.36
- WVE 44.53
- Support Level
- SID $1.56
- WVE $10.79
- Resistance Level
- SID $1.60
- WVE $11.78
- Average True Range (ATR)
- SID 0.05
- WVE 0.69
- MACD
- SID 0.00
- WVE 0.05
- Stochastic Oscillator
- SID 47.22
- WVE 43.95
About SID Companhia Siderurgica Nacional S.A.
Companhia Siderurgica Nacional is an integrated steel producer. The company operate throughout the entire steel production chain, from the mining of iron ore to the production and sale of a diversified range of steel products. It operates in five segments namely, Steel, Mining, Logistics, Energy, and Cement. It generates maximum revenue from the steel segment. Geographically, it derives a majority of revenue from Asia.
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.